Provided by Tiger Trade Technology Pte. Ltd.

Secondary Listings on HKEX

446.381
-1.813-0.40%
Number of Gainers:6
Number of Losers:13
Number of Flat:- -
PE:- -
High:447.991
Open:447.991
Low:440.826
Close:448.194
Volume:71.04M
Turnover:6.77B
Market Cap:4.59T
Float Cap:4.46T

Loading ...

Spot Bitcoin Funds Post Best Monthly Inflow of the Year, Yet Early September Outflow Raises Caution

Deep News
·
Sep 03

HUTCHMED Surges 14% on $1.295 Billion Licensing Deal with GSK for Novel Dual-Targeting Cancer Therapy

Deep News
·
Sep 03

Asian Market Selloff Triggered by Yen Rally While Precious Metals Rebound Lifts Mining Sector

Stock News
·
Sep 03

Market Chatter: Alipay+ Link-Up with UPI Reportedly Faces Delay Amid India's Security Concerns

MT Newswires Live
·
Sep 03

Baozun Reports 187,585,241 Total Issued Shares at Aug. 31, 2026 Monthly Close

Reuters
·
Sep 03

Yum China Files HKEX Next-Day Return Disclosing Share Buyback Cancellation at USD 44.86

Reuters
·
Sep 03

Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%

MT Newswires Live
·
Sep 03

Alibaba Group Holding Stock Sheds 2.2% in Hong Kong

Dow Jones
·
Sep 03

Hong Kong Stocks Close Lower: Hang Seng Dips 0.39%, Tech Index Falls 1.08% as Real Estate Sector Rallies

Deep News
·
Sep 03

Chinese E-Commerce Moves to Next Phase After Delivery Price War Changes Shopping Habits

Reuters
·
Sep 03

Hutchmed China Ltd - Hutchmed Licenses Kras-Egfr-Antibody to GSK

THOMSON REUTERS
·
Sep 03

港股动态:携程股价重挫逾4%,增长减速预期与多重宏观压力引发市场忧虑

Stock News
·
Sep 03

ZTO Express-W Allocates $8.235 Million to Buy Back 391,800 Shares on September 2

Deep News
·
Sep 03

Hutchmed (China) Signs Exclusive Licensing Deal with GSK for Investigational Cancer Drug

Reuters
·
Sep 03

ZTO Express Files HKEX Next-Day Disclosure, Reports Share Repurchase for Cancellation

Reuters
·
Sep 03

Hutchmed (China) - to Start Global Phase 1 Development Program in H2 2026

THOMSON REUTERS
·
Sep 03

Hutchmed Licenses KRAS-EGFR Antibody Conjugate HMPL-A830 to GSK for USD 110 Million Upfront

Reuters
·
Sep 03

Hutchmed (China) - Agreement Includes $110 Mln Upfront, up to $1.30 Bln in Milestones, Plus Royalties

THOMSON REUTERS
·
Sep 03

Hutchmed Announces Licensing Agreement with GSK for Kras-Egfr-Antibody Conjugate Cancer Therapy

THOMSON REUTERS
·
Sep 03

Trip.com Schedules Conference Call on Q2, First-Half 2026 Results

Reuters
·
Sep 02